Stock Track | Bio-Techne Soars 5.83% in Pre-Market on Strong Q2 Earnings Beat

Stock Track

Feb 05, 2025

Shares of Bio-Techne Corporation (NASDAQ: TECH) surged 5.83% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company reported better-than-expected financial results, fueling investor optimism and driving the stock higher.

Bio-Techne reported adjusted earnings per share (EPS) of $0.42 for the quarter ended December 31, 2024, surpassing the analyst consensus estimate of $0.39 by 7.69%. Additionally, the company's quarterly sales of $297.03 million exceeded the analyst consensus estimate of $285.98 million by 3.87%, representing an 8.96% year-over-year increase.

The strong financial performance can be attributed to Bio-Techne's continued growth in its core life sciences business, driven by robust demand for its innovative tools and bioactive reagents used in research and clinical diagnostic applications. The company's ability to consistently deliver solid earnings and revenue growth has reinforced investor confidence, leading to the pre-market surge in its stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122145275"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122145275\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122145275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-05 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122145275","market":"hk","top_or_hot":-1,"title":"Stock Track | Bio-Techne Soars 5.83% in Pre-Market on Strong Q2 Earnings Beat","media":"Stock Track","content":"<p>Shares of Bio-Techne Corporation (NASDAQ: TECH) surged 5.83% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company reported better-than-expected financial results, fueling investor optimism and driving the stock higher.</p>\n\n<p>Bio-Techne reported adjusted earnings per share (EPS) of $0.42 for the quarter ended December 31, 2024, surpassing the analyst consensus estimate of $0.39 by 7.69%. Additionally, the company's quarterly sales of $297.03 million exceeded the analyst consensus estimate of $285.98 million by 3.87%, representing an 8.96% year-over-year increase.</p>\n\n<p>The strong financial performance can be attributed to Bio-Techne's continued growth in its core life sciences business, driven by robust demand for its innovative tools and bioactive reagents used in research and clinical diagnostic applications. The company's ability to consistently deliver solid earnings and revenue growth has reinforced investor confidence, leading to the pre-market surge in its stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bio-Techne Soars 5.83% in Pre-Market on Strong Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bio-Techne Soars 5.83% in Pre-Market on Strong Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-05 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bio-Techne Corporation (NASDAQ: TECH) surged 5.83% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company reported better-than-expected financial results, fueling investor optimism and driving the stock higher.</p>\n\n<p>Bio-Techne reported adjusted earnings per share (EPS) of $0.42 for the quarter ended December 31, 2024, surpassing the analyst consensus estimate of $0.39 by 7.69%. Additionally, the company's quarterly sales of $297.03 million exceeded the analyst consensus estimate of $285.98 million by 3.87%, representing an 8.96% year-over-year increase.</p>\n\n<p>The strong financial performance can be attributed to Bio-Techne's continued growth in its core life sciences business, driven by robust demand for its innovative tools and bioactive reagents used in research and clinical diagnostic applications. The company's ability to consistently deliver solid earnings and revenue growth has reinforced investor confidence, leading to the pre-market surge in its stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"","article_id":"1122145275","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122145275","pubTimestamp":1738756959,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bio-Techne Corporation  surged 5.83% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company reported better-than-expected financial results, fueling investor optimism and driving the stock higher.Bio-Techne reported adjusted earnings per share  of $0.42 for the quarter ended December 31, 2024, surpassing the analyst consensus estimate of $0.39 by 7.69%. Additionally, the company's quarterly sales of $","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation"},"translate_title":"股票赛道Bio-Techne因第二季度盈利强劲而盘前飙升5.83%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1},"content_text":"Shares of Bio-Techne Corporation (NASDAQ: TECH) surged 5.83% in pre-market trading on Wednesday, following the company's impressive second-quarter fiscal 2025 earnings report. The life sciences company reported better-than-expected financial results, fueling investor optimism and driving the stock higher.\nBio-Techne reported adjusted earnings per share (EPS) of $0.42 for the quarter ended December 31, 2024, surpassing the analyst consensus estimate of $0.39 by 7.69%. Additionally, the company's quarterly sales of $297.03 million exceeded the analyst consensus estimate of $285.98 million by 3.87%, representing an 8.96% year-over-year increase.\nThe strong financial performance can be attributed to Bio-Techne's continued growth in its core life sciences business, driven by robust demand for its innovative tools and bioactive reagents used in research and clinical diagnostic applications. The company's ability to consistently deliver solid earnings and revenue growth has reinforced investor confidence, leading to the pre-market surge in its stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}